MedTrace Logo

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

NCT04723394 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 910

Last updated 2023-07-05

Study results available
· View outcomes & findings →

Summary

This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.

Conditions

Interventions

DRUG

AZD7442

Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.

DRUG

Placebo

Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-28
Primary Completion
2021-08-21
Completion
2022-10-19
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Czechia
  • Germany
  • Hungary
  • Italy
  • Japan
  • Mexico
  • Peru
  • Poland
  • Russia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04723394 on ClinicalTrials.gov